What is B-cell malignancy?
What is B-cell malignancy?
A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. There are many different types of B-cell non-Hodgkin lymphomas.
How common are B-cell malignancies?
Demographics. In the United States, B-cell lymphomas comprise about 85% of all NHL. Regarding these B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL) has the highest incidence of 30%, followed by follicular lymphoma (20%).
Is B-cell lymphoma serious?
It’s an aggressive but treatable cancer that can involve lymph nodes and other organs. This is the second most common type on non-Hodgkin’s lymphoma. It’s slow growing and usually starts in the lymph nodes. Generally involves lymph nodes, bone marrow, spleen, and the gastrointestinal system.
What are the stages of B cell lymphoma?
Primary mediastinal B-cell lymphoma. This lymphoma, which starts in the space between the lungs (the mediastinum), is treated like early stage diffuse large B-cell lymphoma. A common treatment is 6 courses of CHOP chemo plus rituximab (R-CHOP). This may be followed by radiation to the mediastinum.
What is the survival rate for B cell lymphoma?
Hodgkin’s lymphoma is treatable, especially in its early stages. The one-year survival rate for all patients diagnosed with Hodgkin’s lymphoma is about 92 percent. The five-year survival rate is about 86 percent.
What is treatment for B cell lymphoma?
Treatment of B-cell lymphoma. The origin of the lymphoma is crucial to determine a proper treatment. The most common treatments to address B-cell lymphoma are radiation therapy, particularly in early stages and to respond to eventual complications; curative and palliative chemotherapy; and biologic therapy.
What is the prognosis for diffuse large B cell lymphoma?
Diffuse large B-cell lymphoma. However, the usual treatment for each of these is chemotherapy, often in combination with an antibody targeted at the tumor cells. Through these treatments, more than half of patients with DLBCL can be cured, and the overall five-year survival rate for older adults is around 58%.
